the importance of targeting tp53 in aml and agents being explored
Published 1 year ago • 373 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
2:02
how to ace your rheumatology interview
-
2:32
how quickly does aml progress? #aml
-
19:30
mechanisms of gene regulation by chromatin adaptor proteins
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:03
significance of p53 mutations in aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
0:46
the prognostic impact of tp53 mutation in mpns
-
1:12
varied outcomes in patients with aml harboring poor-risk cytogenetics with or without tp53 mutation
-
1:39
treatment approaches for patients with tp53m aml ineligible for high intensity chemotherapy
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:27
treatment options for patients with tp53-mutated aml
-
8:14
progress in the treatment of tp53 mutated aml